Published in Cancer Res on February 15, 2007
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet (2010) 3.89
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem (2008) 2.22
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest (2010) 1.74
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest (2007) 1.45
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 1.35
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res (2011) 1.30
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res (2009) 1.21
Similar nucleotide excision repair capacity in melanocytes and melanoma cells. Cancer Res (2010) 1.21
TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res (2012) 1.20
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol (2007) 1.11
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov (2014) 1.10
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev (2008) 1.10
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene (2009) 1.02
Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy (2014) 0.99
Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene (2010) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res (2012) 0.97
Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle (2010) 0.93
Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer (2009) 0.89
Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res (2010) 0.87
A prognostic signature of G(2) checkpoint function in melanoma cell lines. Cell Cycle (2013) 0.86
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol (2013) 0.85
Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov (2015) 0.84
Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol (2007) 0.83
Application of angiogenesis to clinical dermatology. Adv Dermatol (2008) 0.79
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
Mechanisms of chromosomal instability in melanoma. Environ Mol Mutagen (2014) 0.77
Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment. Mol Cancer Res (2014) 0.77
ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma. Mol Cancer Res (2016) 0.75
Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. J Biol Chem (2016) 0.75
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol (2005) 10.44
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (2012) 5.16
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity (2002) 4.87
The Ras superfamily at a glance. J Cell Sci (2005) 4.83
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J Cell Biol (2003) 4.24
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol (2003) 4.22
Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet (2010) 3.89
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 3.64
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci (2004) 3.27
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell (2005) 3.17
Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol (2008) 3.11
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell (2013) 3.04
Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell (2012) 2.98
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol (2004) 2.74
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol (2010) 2.70
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A (2011) 2.63
Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol (2006) 2.61
The dark side of Ras: regulation of apoptosis. Oncogene (2003) 2.60
Focus on bladder cancer. Cancer Cell (2004) 2.59
Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge. Cell (2007) 2.59
Signaling interplay in Ras superfamily function. Curr Biol (2005) 2.59
A universal trend of reduced mRNA stability near the translation-initiation site in prokaryotes and eukaryotes. PLoS Comput Biol (2010) 2.57
The human Tim/Tipin complex coordinates an Intra-S checkpoint response to UV that slows replication fork displacement. Mol Cell Biol (2007) 2.54
Long-term preservation of antigenicity on tissue microarrays. Lab Invest (2004) 2.44
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem (2003) 2.44
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol (2008) 2.43
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med (2002) 2.39
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
Coronin 1B antagonizes cortactin and remodels Arp2/3-containing actin branches in lamellipodia. Cell (2008) 2.28
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res (2007) 2.26
New insights into the regulation and cellular functions of the ARP2/3 complex. Nat Rev Mol Cell Biol (2012) 2.25
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol (2005) 2.24
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem (2008) 2.22
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem (2007) 2.20
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Mol Cell Biol (2002) 2.19
Ras history: The saga continues. Small GTPases (2010) 2.18
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
Ligand-dependent dynamics and intramolecular signaling in a PDZ domain. J Mol Biol (2004) 2.17
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood (2011) 2.16
Structural basis for the selective activation of Rho GTPases by Dbl exchange factors. Nat Struct Biol (2002) 2.14
Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14
Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol (2002) 2.12
Implication of DNA polymerase lambda in alignment-based gap filling for nonhomologous DNA end joining in human nuclear extracts. J Biol Chem (2003) 2.09
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther (2003) 2.08
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03
Conversion of phosphoglycolate to phosphate termini on 3' overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J Biol Chem (2002) 2.03
Coronins: the return of the crown. Trends Cell Biol (2006) 2.02
Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res (2004) 2.01
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99